1. Scrip

Cellerant adds two new management components

 
• By Lily Skeet Hodgson

Cellerant Therapeutics, a biotechnology company which specialises in therapies for blood disorders, has appointed Dr Margaret Dillon as vice president of regulatory affairs and Dr Robert Tressler as vice president of research and development. Dr Dillon comes to Cellerant with 19 years of experience in pharmaceutical regulatory affairs, most recently with CV Therapeutics (now Gilead Sciences). Dr Tressler brings to the table 20 years of industry experience in oncology, cardiovascular and immunological indications. Most recently, he served as executive director of research for Geron.

Cellerant Therapeutics, a biotechnology company which specialises in therapies for blood disorders, has appointed Dr Margaret Dillon as vice president of regulatory affairs and Dr Robert Tressler as vice president of research and development. Dr Dillon comes to Cellerant with 19 years of experience in pharmaceutical regulatory affairs, most recently with CV Therapeutics (now Gilead Sciences). Dr Tressler brings to the table 20 years of industry experience in oncology, cardiovascular and immunological indications. Most recently, he served as executive director of research for Geron.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

AstraZeneca Pledges Big Investment In US Manufacturing Amid Tariff Threats

 
• By Alaric DeArment and Sarah Karlin-Smith

The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.